...
首页> 外文期刊>Clinical lung cancer >Prognostic value of apoptosis-associated speck-like protein containing a CARD gene promoter methylation in resectable non-small-cell lung cancer.
【24h】

Prognostic value of apoptosis-associated speck-like protein containing a CARD gene promoter methylation in resectable non-small-cell lung cancer.

机译:包含CARD基因启动子甲基化的凋亡相关斑点样蛋白在可切除的非小细胞肺癌中的预后价值。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The apoptosis-associated speck-like protein containing a CARD (ASC) is a newly identified tumor suppressor gene that is frequently inactivated by de novo promoter methylation in non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: We studied 79 patients with NSCLC who had undergone surgery with curative intent. The ASC promoter methylation status was determined by methylation-specific polymerase chain reaction. Statistical analyses (all 2-sided) were performed to determine the prognostic effect of hypermethylation on various clinical parameters. RESULTS: ASC promoter hypermethylation was detectable by methylation-specific polymerase chain reaction in 9 of 70 (12.9%) normal lungs and in 33 of 70 (47.1%) matching tumor samples of patients with NSCLC. The mean ASC methylation level was significantly higher in tumor than in matching normal tissue (P < 0.001). ASC methylation in normal tissue was always accompanied with ASC methylation in matching tumor tissue. Patients without ASC promoterhypermethylation showed a significantly better survival than patients with ASC promoter hypermethylation (P = 0.007). Multivariate analysis revealed ASC promoter methylation as an independent unfavorable prognostic factor (P = 0.009). CONCLUSION: Our results indicate that ASC promoter hypermethylation is a common event in patients with primary NSCLC, and this epigenetic alteration is associated with inferior survival, suggesting that ASC promoter hypermethylation might be an important biomarker for a biologic, aggressive disease in NSCLC.
机译:背景:含有CARD(ASC)的凋亡相关斑点样蛋白是一种新近鉴定的肿瘤抑制基因,在非小细胞肺癌(NSCLC)中经常被从头启动子甲基化失活。患者与方法:我们研究了79例行根治性手术的NSCLC患者。通过甲基化特异性聚合酶链反应确定ASC启动子的甲基化状态。进行统计分析(全两面)以确定甲基化过高对各种临床参数的预后影响。结果:通过甲基化特异性聚合酶链反应可在70例正常肺中的9例(12.9%)和70例非小细胞肺癌匹配的肿瘤样本中的33例(47.1%)中检测到ASC启动子超甲基化。肿瘤中的平均ASC甲基化水平显着高于匹配的正常组织(P <0.001)。正常组织中的ASC甲基化总是与匹配的肿瘤组织中的ASC甲基化相伴。没有ASC启动子高甲基化的患者生存率明显高于ASC启动子高甲基化的患者(P = 0.007)。多变量分析显示ASC启动子甲基化是一个独立的不利预后因素(P = 0.009)。结论:我们的结果表明,ASC启动子高甲基化是原发性NSCLC患者的常见事件,这种表观遗传学改变与生存期较低有关,表明ASC启动子高甲基化可能是NSCLC生物学,侵袭性疾病的重要生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号